CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until eit...
Phase 2
Ann Arbor, Michigan, United States and 28 other locations
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial...
Phase 2
Detroit, Michigan, United States and 65 other locations
participants with recurrent or primary advanced (Stage III or IV) endometrial cancer....
Phase 3
Detroit, Michigan, United States and 168 other locations
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in...
Phase 2
Detroit, Michigan, United States and 16 other locations
in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), platinum-re ...
Phase 1
Detroit, Michigan, United States and 17 other locations
is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate effect of XmAb541 on tumor...
Phase 1
Detroit, Michigan, United States and 6 other locations
This study will test the safety, including side effects, and determine the characteristics of a drug called PRO1184 in participants with solid tumors...
Phase 1, Phase 2
Detroit, Michigan, United States and 31 other locations
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future st...
Phase 1
Detroit, Michigan, United States and 4 other locations
in participants with platinum-resistant ovarian carcinoma, endometrial adenocarcinoma, and urothelial carcinoma based on Acrivon's OncoSigna...
Phase 1, Phase 2
Detroit, Michigan, United States and 66 other locations
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Phase 1
Detroit, Michigan, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal